Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6217-54-5

Post Buying Request

6217-54-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6217-54-5 Usage

Description

Different sources of media describe the Description of 6217-54-5 differently. You can refer to the following data:
1. Docosa Hexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, sperm, testicles and retina. It can be synthesized from alphalinolenic acid or obtained directly from maternal milk or fish oil. DHA's structure is a carboxylic acid(~oic acid) with a 22-carbon chain (docosa- is Greek for 22) and six (Greek "hexa") cis double bonds (-en~); the first double bond is located at the third carbon from the omega end. Its trivial name is cervonic acid, its systematic name is all-cis-docosa-4,7,10,13,16,19-hexa-enoic acid, and its shorthand name is 22:6(n-3) in the nomenclature of fatty acids.
2. Docosahexaenoic acid (DHA) is a long-chain ω-3 polyunsaturated fatty acid (PUFA) found in fish and algal oils. It comprises approximately 40% of total brain PUFAs and is abundant in grey matter and retinal membranes. DHA typically represents 0.52-7.5% of human total plasma fatty acids. It is produced from α-linolenic acid (ALA; Item Nos. 90210 | 21910) via a series of desaturase- and elongase-catalyzed reactions, resulting in a docosapentaenoic acid (DPA; ) intermediate, which is elongated, desaturated, and β-oxidized to produce DHA. DHA can be liberated from cellular membranes by phospholipase A2 (PLA2) and converted to numerous oxylipins, including specialized pro-resolving mediators (SPMs), which are produced by lipoxygenases and include D-series protectins and resolvins, as well as maresins, that regulate host defense and the resolution of inflammation. DHA has roles in several physiological and pathological processes, including neural development, cardiovascular diseases, obesity, and inflammation. DHA MaxSpec? standard is a quantitative grade standard of DHA that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. The verified concentration is provided on the certificate of analysis. This DHA MaxSpec? standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

Application

DHA is used as a supplement for premature babies and as an ingredient in baby formula during the first year of life to promote better mental development. It is also used in infant formula to prevent lung diseases, allergic diseases such as eczema or hay fever, and diarrhea. This practice probably started because DHA is found naturally in breast milk. In some cases, DHA is used in combination with arachidonic acid. DHA is also taken by mouth alone or along with EPA to improve mental function in healthy people or those with mental impairment. It is also used to improve mental function in people with dementia or age-related mental decline. It is also taken by mouth for attention deficit-hyperactivity disorder (ADHD), depression, aggressive behavior, Alzheimer's disease, autism, and to prevent relapse in schizophrenic patients who stop taking antipsychotic medication. DHA is also taken by mouth for diabetes, coronary artery disease (CAD), stroke, high levels of cholesterol and fats in the blood, high blood pressure, and cancer including breast and prostate cancer. It is also used for a type of fatty liver not related to drinking alcohol, obesity, ear infections, and learning problems in children. Some people use DHA is for improving vision, preventing an eye disease called age-related macular degeneration (AMD), treating an eye condition called retinitis pigmentosa, and increasing DHA levels in people with cystic fibrosis. DHA is taken by mouth in combination with eicosapentaenoic acid (EPA) for a variety of conditions, including the prevention and reversal of heart disease, stabilizing heart rhythm, preventing abnormal heart beats after heart surgery, painful menstrual periods, lupus, and certain kidney diseases. EPA and DHA are also used in combination for preventing migraine headaches in teenagers, Behcet's syndrome, psoriasis, Raynaud's syndrome, rheumatoid arthritis, bipolar disorder, and ulcerative colitis.

Biosynthesis of DHA

ALA is an essential fatty acid. It is synthesised in plants and in many lower organisms and is found in the human diet mainly as a component of green leaves, some nuts, seeds and vegetable oils, and foods made from or containing those ingredients. There is a metabolic pathway that links ALA to DHA. This pathway involves a series of enzyme-catalysed elongation and desaturation reactions. Elongation enzymes, called elongases, add pairs of carbon atoms to the growing acyl chain, in this case converting an 18-carbon fatty acid into a 22-carbon one, while desaturase enzymes insert double bonds into the acyl chain, in this case converting a fatty acid with 3 double bonds in its acyl chain into one with 6 double bonds. These reactions occur predominantly within the endoplasmic reticulum. The pathway is believed to mainly occur within the liver, but there is some evidence that other tissues, including brain and testis, have high expression of the genes encoding the relevant enzymes.

Chemical Properties

Clear Colourless Liquid

Occurrence

Ordinary types of cooked salmon contain 500 – 1500 mg DHA and 300–1000 mg EPA per 100 grams.(USDA) Additional top fish sources of DHA are: tuna, bluefish, mackerel, swordfish, anchovies, herring, sardines, and caviar. The discovery of algae - based DHA In the early 1980s, NASA sponsored scientific research in search of a plant-based food source that could generate oxygen and nutrition on long-duration space flights. The researchers discovered that certain species of marine algae produced rich nutrients. This research led to the development of an algae-based, vegetable-like oil that contains two essential polyunsaturated fatty acids: DHA and ARA (Arachidonic acid). Use as a food additive DHA is widely used as a food supplement. It was first used primarily in infant formulas. In 2004, the US Food and Drug Administration endorsed qualified health claims for DHA , and by 2007 DHA - fortified dairy items (milk, yogurt, cooking oil) started to appear in grocery stores. DHA is believed to be helpful to people with a history of heart disease, for premature infants, and to support healthy brain development especially in young children along with supporting retinal development. Some manufactured DHA is a vegetarian product extracted from algae, and it competes on the market with fish oil that contains DHA and other omega-3's such as EPA. Both fish oil and DHA are odorless and tasteless after processing as a food additive. Studies of vegetarians and vegans Vegetarian diets typically contain limited amounts of DHA, and vegan diets typically contain no DHA. Vegetarians and vegans have substantially lower levels of DHA in their bodies, and short-term supplemental ALA has been shown to increase EPA, but not DHA. However, supplemental preformed DHA, available in algae-derived oils or capsules, has been shown to increase DHA levels. While there is little evidence of adverse health or cognitive effects due to DHA deficiency in adult vegetarians or vegans, fetal and breast milk levels remain a concern. DHA and EPA in fish oils Fish oil is widely sold in gelatin capsules containing a mixture of omega-3 fatty acids including EPA and smaller quantities of DHA. One study found fish oil higher in DHA than EPA lowered inflammatory cytokines, such as IL-6 and IL-1β, associated with neurodegenerative and autoimmune diseases. They note the brain normally contains DHA, but not EPA, though both DHA and EPA plasma concentrations increased significantly for participants.

Uses

Docosahexaenoic acid is found in fish oils in nature. It is also commercially manufactured from microalgae; Crypthecodinium cohnii and Schizochytrium.

Definition

ChEBI: A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.

General Description

An omega-3 fatty acid essential for normal brain growth andfunction, docosahexaenoic acid (DHA) plays an important role as a signaling factor in cells for both anti- and pro-inflammatory processes. Levels of docosahexaenoic acid as well as other fatty acids are analyzed by GC/MS or LC-MS/MS methods to monitor patients undergoing diet therapy for mitochondrial or peroxisomal disorders. This Certified Spiking Solution? is suitable for use as starting material in thepreparation of linearity standards, calibrators, or controls in mass spectrometry-based DHA testing applications such as assessment of cardiovascular disease risk and fatty acid deficiency, and detection and quantification of DHA in nutraceuticals and dietary supplements.

Biological Activity

Endogenous omega-3 fatty acid. Acts as a selective retinoid X receptor (RXR) agonist that displays no activity at RAR, thyroid hormone receptor or the vitamin D receptor (VDR). Activates all three RXR isoforms. Also shown to inhibit A β 1-42 fibrillation and toxicity in vitro .

Biochem/physiol Actions

Docosahexaenoic acid, DHA, is an omega-3 polyunsaturated fatty acid with 22 carbons and six double bonds, the first double bond occuring at position three from the methyl terminus (22:6 n-3). DHA is a component of lipid membranes and the myelin sheath. DHA also serves as a precursor for signaling molecules such as prostaglandins and eicosanoids.

Purification Methods

Its solubility in CHCl3 is 5%. It has been purified from fish oil by GLC using Ar as mobile phase and EGA as stationary phase with an ionisation detector [UV: Stoffel & Ahrens J Lipid Res 1 139 1959], and via the ester by evaporative "molecular" distillation using a 'continuous molecular still' at 10-4 mm with the highest temperature being 110o and a total contact time with the hot surface being 60sec [Farmer & van den Heuvel J Chem Soc 427 1938]. The methyl ester has b 208-211o/2mm, d4 0.9398, 20 1.5035. nD With Br2 it forms a dodecabromide m ca 240o(dec). Also, the acid was converted to the methyl ester and purified through a three-stage molecular still [as described by Sutton Chem Ind (London) 11383 1953] at 96o, and the rate was adjusted so that one-third of the material was removed each cycle of three distillations. The distillate (numbered 4) (13g) was dissolved in EtOH (100mL containing 8g of KOH) at -70o and set aside for 4hours at 30o with occasional shaking under a vacuum. Water (100mL) was added and the solution was extracted with pentane, washed with HCl, dried (MgSO4), filtered and evaporated to give a clear oil (11.5g) m -44.5o to -44.1o. In the catalytic hydrogenation of the oil six mols of H2 are absorbed and docosanoic acid (behenic acid) is produced with m 79.0-79.3o undepressed with an authentic sample (see docosanoic acid below) [Whitcutt Biochem J 67 60 1957]. [Beilstein 2 IV 1812.]

Check Digit Verification of cas no

The CAS Registry Mumber 6217-54-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,2,1 and 7 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 6217-54:
(6*6)+(5*2)+(4*1)+(3*7)+(2*5)+(1*4)=85
85 % 10 = 5
So 6217-54-5 is a valid CAS Registry Number.
InChI:InChI=1/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3+,7-6+,10-9+,13-12+,16-15+,19-18-

6217-54-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (D2534)  cis-4,7,10,13,16,19-Docosahexaenoicacid  ≥98%

  • 6217-54-5

  • D2534-25MG

  • 499.59CNY

  • Detail
  • Sigma

  • (D2534)  cis-4,7,10,13,16,19-Docosahexaenoicacid  ≥98%

  • 6217-54-5

  • D2534-100MG

  • 1,305.72CNY

  • Detail
  • Sigma

  • (D2534)  cis-4,7,10,13,16,19-Docosahexaenoicacid  ≥98%

  • 6217-54-5

  • D2534-1G

  • 4,580.55CNY

  • Detail

6217-54-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name all-cis-docosa-4,7,10,13,16,19-hexaenoic acid

1.2 Other means of identification

Product number -
Other names Cervicarcin,hemihydrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6217-54-5 SDS

6217-54-5Synthetic route

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
With ethylenediaminetetraacetic acid; edetate disodium In ethanol; water at 60 - 65℃; for 2h;98%
With sodium hydroxide; edetate disodium In ethanol at 65℃;98%
Stage #1: all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate With water; sodium hydroxide In methanol at 20℃; for 1.5h;
Stage #2: With hydrogenchloride In methanol; water Cooling with ice;
91%
docosahexaenoic acid ethyl ester

docosahexaenoic acid ethyl ester

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
With lithium hydroxide monohydrate In ethanol; water at 60℃; for 1h; Inert atmosphere;94%
all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester
2566-90-7

all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
With lithium hydroxide In tetrahydrofuran; water92%
Stage #1: all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester With water; lithium hydroxide In tetrahydrofuran at 0 - 20℃; for 12h;
Stage #2: With citric acid In water at 0℃; pH=~ 4;
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

serinol
534-03-2

serinol

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxypropan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxypropan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 4h; Green chemistry; Enzymatic reaction;A n/a
B 87%
3-Amino-1,2-propanediol
616-30-8, 13552-31-3

3-Amino-1,2-propanediol

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2,3-dihydroxypropyl)docosa-4,7,10,13,16,19-hexaenamide
1048012-06-1

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2,3-dihydroxypropyl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 80%
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

ethanolamine
141-43-5

ethanolamine

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

N-docosahexaenoylethanolamine
162758-94-3

N-docosahexaenoylethanolamine

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 75%
(R)-2-aminopropan-1-ol
35320-23-1

(R)-2-aminopropan-1-ol

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((R)-1-hydroxypropan-2-yl)docosa-4,7,10,13,16,19-hexaenamide
1282618-08-9

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((R)-1-hydroxypropan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 70%
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

(R)-3-amino-1,2-propanediol
66211-46-9

(R)-3-amino-1,2-propanediol

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

C25H39NO3

C25H39NO3

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 70%
(S)-3-Amino-1,2-propanediol
61278-21-5

(S)-3-Amino-1,2-propanediol

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

C25H39NO3

C25H39NO3

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 65%
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

ethylenediamine
107-15-3

ethylenediamine

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

(4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoic acid [2-((4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoylamino)ethyl]amide
1333067-15-4

(4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoic acid [2-((4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoylamino)ethyl]amide

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 60%
serin
302-84-1

serin

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

C25H37NO4

C25H37NO4

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 55%
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

1,3-Diamino-2-hydroxypropane
616-29-5

1,3-Diamino-2-hydroxypropane

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

C25H40N2O2

C25H40N2O2

C

C47H70N2O3

C47H70N2O3

Conditions
ConditionsYield
With Novozym 435 lipase on resin In acetone at 35℃; for 8h; Green chemistry; Enzymatic reaction;A n/a
B 48%
C 38%
C25H40O2Si

C25H40O2Si

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
With sodium thiosulfate In water Yield given;
(Z)-3-Hexen-1-ol
928-96-1

(Z)-3-Hexen-1-ol

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: pyridine, Ph3PBr2 / acetonitrile / 0 °C
2: acetonitrile / 24 h / Heating
3: 56 percent / NaN(SiMe3)2 / tetrahydrofuran / 1.) room temperature, 2.) -90 deg C
4: 100 percent / H+ / tetrahydrofuran
5: 86 percent / LiAlH4 / tetrahydrofuran / -70 °C
6: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
7: 95 percent / acetonitrile / Heating
8: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
9: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
1-bromo-3-hexene
84254-20-6

1-bromo-3-hexene

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: acetonitrile / 24 h / Heating
2: 56 percent / NaN(SiMe3)2 / tetrahydrofuran / 1.) room temperature, 2.) -90 deg C
3: 100 percent / H+ / tetrahydrofuran
4: 86 percent / LiAlH4 / tetrahydrofuran / -70 °C
5: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
6: 95 percent / acetonitrile / Heating
7: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
8: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(3Z,6Z,9Z)-dodecatrien-1-ol
81345-02-0

(3Z,6Z,9Z)-dodecatrien-1-ol

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
2: 95 percent / acetonitrile / Heating
3: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
4: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(3Z)-3-hexenyltriphenylphosphonium bromide
21676-05-1

(3Z)-3-hexenyltriphenylphosphonium bromide

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 56 percent / NaN(SiMe3)2 / tetrahydrofuran / 1.) room temperature, 2.) -90 deg C
2: 100 percent / H+ / tetrahydrofuran
3: 86 percent / LiAlH4 / tetrahydrofuran / -70 °C
4: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
5: 95 percent / acetonitrile / Heating
6: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
7: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z)-6,6-diisopropoxyhex-3-en-1-al
162758-88-5

(Z)-6,6-diisopropoxyhex-3-en-1-al

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 51 percent / NaN(SiMe3)2 / tetrahydrofuran / 1.) room temperature, 2.) -90 deg C
2: H+ / tetrahydrofuran
3: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
4: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z,Z)-1-bromododeca-3,6,9-triene
169900-26-9

(Z,Z,Z)-1-bromododeca-3,6,9-triene

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 95 percent / acetonitrile / Heating
2: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
3: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z,Z)-dodeca-3,6,9-trien-1-al
169900-23-6

(Z,Z,Z)-dodeca-3,6,9-trien-1-al

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 86 percent / LiAlH4 / tetrahydrofuran / -70 °C
2: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
3: 95 percent / acetonitrile / Heating
4: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
5: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z)-10-oxodeca-4,7-dienoic acid methyl ester
169900-28-1

(Z,Z)-10-oxodeca-4,7-dienoic acid methyl ester

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
2: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z,Z)-1,1-diisopropoxydodeca-3,6,9-triene
169900-22-5

(Z,Z,Z)-1,1-diisopropoxydodeca-3,6,9-triene

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 100 percent / H+ / tetrahydrofuran
2: 86 percent / LiAlH4 / tetrahydrofuran / -70 °C
3: 94 percent / CBr4, Ph3P / CH2Cl2 / 1.) 0 deg C, 15 min, 2.) room temperature, 1 h
4: 95 percent / acetonitrile / Heating
5: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
6: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z)-10,10-diisopropoxydeca-4,7-dienoic acid methyl ester
169900-25-8

(Z,Z)-10,10-diisopropoxydeca-4,7-dienoic acid methyl ester

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: H+ / tetrahydrofuran
2: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
3: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
(Z,Z,Z)-dodeca-3,6,9-trienyltriphenylphosphonium bromide

(Z,Z,Z)-dodeca-3,6,9-trienyltriphenylphosphonium bromide

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / NaN(SiMe3)2 / tetrahydrofuran / -80 °C
2: 92 percent / LiOH / tetrahydrofuran; H2O
View Scheme
5-((3Z,6Z,9Z,12Z,15Z)-1-iodooctadeca-3,6,9,12,15-pentaenyl)dihydro-2(3H)-furanone
78144-19-1

5-((3Z,6Z,9Z,12Z,15Z)-1-iodooctadeca-3,6,9,12,15-pentaenyl)dihydro-2(3H)-furanone

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium iodide / acetonitrile / 1 h / 23 °C
2: sodium thiosulfate / H2O
View Scheme
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

eicosapentaenoic acid ethyl ester
86227-47-6

eicosapentaenoic acid ethyl ester

A

all cis-5,8,11,14,17-eicosapentaenoic acid
10417-94-4

all cis-5,8,11,14,17-eicosapentaenoic acid

B

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Stage #1: all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate; eicosapentaenoic acid ethyl ester With water; sodium hydroxide In methanol at 20℃; for 1.5h;
Stage #2: With hydrogenchloride In water Cooling with ice;
D-glucose
50-99-7

D-glucose

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
Stage #1: D-glucose; Labyrinthulae strain mh313 microorganism In water at 28℃; for 96h; pH=6.0; Enzymatic reaction;
Stage #2: With hydrogenchloride; methanol Product distribution / selectivity;
carbon dioxide
124-38-9

carbon dioxide

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

Conditions
ConditionsYield
With Nannochloropsis Gaditana Microbiological reaction; Photolysis; Large scale;
all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate
81926-94-5

all-(Z)-ethyl 4,7,10,13,16,19-docosahexaenoate

glycerol
56-81-5

glycerol

A

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

B

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2,3-dihydroxy-propyl ester

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2,3-dihydroxy-propyl ester

C

1,3-didocosahexaenoylglycerol

1,3-didocosahexaenoylglycerol

Conditions
ConditionsYield
With Novozyme 435 immobilized on polystyrene at 35℃; for 24h; Solvent; Green chemistry; Enzymatic reaction;
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester
2566-90-7

all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester

Conditions
ConditionsYield
In diethyl ether100%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl chloride
98776-99-9

(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl chloride

Conditions
ConditionsYield
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 0 - 20℃; for 2h;100%
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 2h; Cooling with ice;100%
With oxalyl dichloride In chloroform for 2h;
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(±)-19,20-epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid
895127-62-5

(±)-19,20-epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid

Conditions
ConditionsYield
With human recombinant cytochrome P450 1A1 Enzymatic reaction; stereoselective reaction;100%
With MS-PPOH
all cis-5,8,11,14,17-eicosapentaenoic acid
10417-94-4

all cis-5,8,11,14,17-eicosapentaenoic acid

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

magnesium bis(lysinate) trihydrate

magnesium bis(lysinate) trihydrate

magnesium Bis-Lysinate Mono-EPA Mono-DHA dihydrate

magnesium Bis-Lysinate Mono-EPA Mono-DHA dihydrate

Conditions
ConditionsYield
With Tocopherol In methanol; ethyl acetate at 50℃; for 0.333333h; Inert atmosphere;100%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

1-t-Butoxycarbonylpiperazine
57260-71-6

1-t-Butoxycarbonylpiperazine

tert-butyl 4-(4Z,7Z,10Z,13Z,16Z, 19Z)-docosa-4,7,10,13,16,19-hexaenoylpiperazine-1-carboxylate
1204318-13-7

tert-butyl 4-(4Z,7Z,10Z,13Z,16Z, 19Z)-docosa-4,7,10,13,16,19-hexaenoylpiperazine-1-carboxylate

Conditions
ConditionsYield
With triethylamine; HATU In acetonitrile at 20℃; for 16h;99%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

1,2-di-O-palmitoyl-sn-glycerol
6076-30-8

1,2-di-O-palmitoyl-sn-glycerol

1-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)-2,3-dihexadecanoyl-sn-glycerol

1-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)-2,3-dihexadecanoyl-sn-glycerol

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Steglich Esterification;99%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(2R)-1,2-bis-O-stearylglycerol
1429-59-0

(2R)-1,2-bis-O-stearylglycerol

1-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)-2,3-dioctadecanoyl-sn-glycerol

1-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)-2,3-dioctadecanoyl-sn-glycerol

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Steglich Esterification;99%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

[3H]-Docosahexaenoic acid-Paclitaxel

[3H]-Docosahexaenoic acid-Paclitaxel

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1 - 2h;98%
With dmap; dacarbazine In dichloromethane at 20℃;
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

calcium bis(lysinate) monohydrate

calcium bis(lysinate) monohydrate

calcium bis-lysinate bis-DHA

calcium bis-lysinate bis-DHA

Conditions
ConditionsYield
In methanol at 50℃; Inert atmosphere;98%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

5-((3Z,6Z,9Z,12Z,15Z)-1-iodooctadeca-3,6,9,12,15-pentaenyl)dihydro-2(3H)-furanone
78144-19-1

5-((3Z,6Z,9Z,12Z,15Z)-1-iodooctadeca-3,6,9,12,15-pentaenyl)dihydro-2(3H)-furanone

Conditions
ConditionsYield
With hydrogen iodide; iodine; potassium hydrogencarbonate In ethanol at 0 - 4℃; for 18h; Inert atmosphere; Darkness;97%
With 2,6-dimethylpyridine; iodine In dichloromethane at 0℃; for 15h; Inert atmosphere; Cooling with ice;96%
With iodine; potassium hydrogencarbonate; potassium iodide In tetrahydrofuran; water for 48h; Ambient temperature;95%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

glycine ethyl ester hydrochloride
5680-79-5

glycine ethyl ester hydrochloride

methyl 2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)acetate

methyl 2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)acetate

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid; glycine ethyl ester hydrochloride With dmap; triethylamine In dichloromethane at 20℃; for 0.0833333h;
Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Inert atmosphere;
97%
With benzotriazol-1-ol; 1,2-dichloro-ethane; triethylamine In dichloromethane at 20℃; for 18h;55%
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 18h;55%
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 18h;55%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

L-valyl-L-lysine
22677-62-9

L-valyl-L-lysine

L-valyl-L-lysine DHA salt

L-valyl-L-lysine DHA salt

Conditions
ConditionsYield
With Tocopherol In ethanol; ethyl acetate at 60℃;97%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

ethanolamine
141-43-5

ethanolamine

N-docosahexaenoylethanolamine
162758-94-3

N-docosahexaenoylethanolamine

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: ethanolamine In dichloromethane for 12h;
96%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Inert atmosphere;92%
With Novozym 435, consisting of immobilized Candida antarctica lipase B In acetonitrile at 40℃; for 15h; Enzymatic reaction;20%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

magnesium bis-lysinate monohydrate

magnesium bis-lysinate monohydrate

magnesium bis-lysinate bis-DHA dihydrate

magnesium bis-lysinate bis-DHA dihydrate

Conditions
ConditionsYield
With Tocopherol In methanol; ethyl acetate at 50℃; for 0.333333h; Inert atmosphere;96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-N-hydroxydocosa-4,7,10,13,16,19-hexaenamide
89017-02-7

(4Z,7Z,10Z,13Z,16Z,19Z)-N-hydroxydocosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: With hydroxylamine In dichloromethane for 12h;
96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: With ammonia In dichloromethane for 12h;
96%
pyrrolidine
123-75-1

pyrrolidine

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(pyrrolidin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(pyrrolidin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: pyrrolidine In dichloromethane for 12h;
96%
piperidine
110-89-4

piperidine

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(piperidin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(piperidin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: piperidine In dichloromethane for 12h;
96%
morpholine
110-91-8

morpholine

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-1-morpholinodocosa-4,7,10,13,16,19-hexaen-1-one

(4Z,7Z,10Z,13Z,16Z,19Z)-1-morpholinodocosa-4,7,10,13,16,19-hexaen-1-one

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: morpholine In dichloromethane for 12h;
96%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Inert atmosphere;
1-methyl-piperazine
109-01-3

1-methyl-piperazine

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(4-methylpiperazin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

(4Z,7Z,10Z,13Z,16Z,19Z)-1-(4-methylpiperazin-1-yl)docosa-4,7,10,13,16,19-hexaen-1-one

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: 1-methyl-piperazine In dichloromethane for 12h;
96%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Inert atmosphere;
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

benzylamine
100-46-9

benzylamine

(4Z,7Z,10Z,13Z,16Z,19Z)-N-benzyldocosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-benzyldocosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: benzylamine In dichloromethane for 12h;
96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

rac-methylbenzylamine
618-36-0

rac-methylbenzylamine

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: rac-methylbenzylamine In dichloromethane for 12h;
96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(R)-1-phenyl-ethyl-amine
3886-69-9

(R)-1-phenyl-ethyl-amine

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((S)-1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((S)-1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: (R)-1-phenyl-ethyl-amine In dichloromethane for 12h;
96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(S)-1-phenyl-ethylamine
2627-86-3

(S)-1-phenyl-ethylamine

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((R)-1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-((R)-1-phenylethyl)docosa-4,7,10,13,16,19-hexaenamide

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With 1,1'-carbonyldiimidazole In dichloromethane at 20℃; for 0.5h;
Stage #2: (S)-1-phenyl-ethylamine In dichloromethane for 12h;
96%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

1,3-dilauroylglycerol
539-93-5

1,3-dilauroylglycerol

1,3-dilauroyl-2-docosahexaenoylglycerol

1,3-dilauroyl-2-docosahexaenoylglycerol

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 15h;95%
With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 80h;25%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 24h;
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

glycerol 1,3-dimyristate
7770-09-4

glycerol 1,3-dimyristate

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2-tetradecanoyloxy-1-tetradecanoyloxymethyl-ethyl ester

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2-tetradecanoyloxy-1-tetradecanoyloxymethyl-ethyl ester

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 15h;95%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride
5680-80-8

methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride

N-docasahexanoyl-L-serine methyl ester

N-docasahexanoyl-L-serine methyl ester

Conditions
ConditionsYield
With triethylamine; carbonochloridic acid, butyl ester In tetrahydrofuran; methanol; acetonitrile at 20℃; for 2h;95%
docosahexaenoic acid
6217-54-5

docosahexaenoic acid

(R)-1-O-octadecyl-3-decanoyl-sn-glycerol
1278408-35-7

(R)-1-O-octadecyl-3-decanoyl-sn-glycerol

(R)-1-O-octadecyl-2-docosahexaenoyl-3-decanoyl-sn-glycerol
1278408-81-3

(R)-1-O-octadecyl-2-docosahexaenoyl-3-decanoyl-sn-glycerol

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 15h; Inert atmosphere;95%

6217-54-5Relevant articles and documents

Synthesis of all-Z-1,6,9,12,15-octadecapenten-3-one, a vinyl ketone polyunsaturated marine natural product isolated from callysponga sp

Langseter, Anne Marie,Stenstroom, Yngve,Skattebool, Lars

, p. 3804 - 3812 (2014)

The synthesis of the marine natural product 1,6Z,9Z,12Z,15Z- octadecapentaen- 3-one (1) has been achieved by two different routes starting from the ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively. Using EPA ethyl ester as starting material the polyunsaturated vinyl ketone lipid 1 was obtained in 17% overall yield.

PROCESSES IN THE PREPARATION OF POLYUNSATURATED KETONE COMPOUNDS

-

Page/Page column 36-37, (2019/12/04)

A process comprising the following steps: a-i) treating a polyunsaturated ester with a base in a solvent of lower alcohol and water to form the corresponding polyunsaturated acid; a-ii) treating the product from step a-i), especially the crude product, with a halolactonization agent in the solvent of lower alcohol and water, to form the corresponding polyunsaturated halolactone; and a-iii) treating the product from step a-ii), especially the crude product, with a reagent in the solvent of lower alcohol and water to convert the polyunsaturated halolactone to the corresponding polyunsaturated epoxide lower alkyl ester.

PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND

-

Page/Page column 21; 22, (2015/02/19)

The invention relates to the manufacture of certain polyunsaturated compounds employing a particular application of the Mitsonobu reaction in the presence of at least one anti-oxidant. We have found a method of making a pharmaceutically-acccptable polyunsaturated ester or thioester compound directly, which can ultimately be converted to the advantageous ketone compounds, in which unwanted oxidation and cis/trans isomerization are substantially reduced or eliminated using particular Mitsonobu chemistry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6217-54-5